Giunti Sara, Cooper Mark
Danielle Alberti Memorial Centre for Diabetic Complications, Vascular Division, Wynn Domain, Baker Heart Research Institute, Melbourne, Australia.
J Clin Hypertens (Greenwich). 2006 Feb;8(2):108-13. doi: 10.1111/j.1524-6175.2005.04508.x.
Hypertension is commonly associated and acts synergistically with diabetes in increasing the risk of macrovascular and microvascular diabetic complications. Large-scale clinical trials have demonstrated that this risk is significantly reduced by intensive antihypertensive treatment, and accordingly, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guideline has further lowered the blood pressure goals for diabetic subjects to <130/80 mm Hg. This implies that most diabetic patients will require the combination of two or more antihypertensive agents to achieve this blood pressure target. Although the most effective combination strategy in diabetes has not yet been determined in large-scale randomized clinical trials, a combination that includes at least one agent that interrupts the renin-angiotensin system appears to not only have a good safety profile, but may also provide additional renal and cardiovascular protection. Other antihypertensive agents should be added based on the patients risk profile and overall treatment regimen to achieve blood pressure goal.
高血压通常与糖尿病相关,并在增加大血管和微血管糖尿病并发症风险方面起协同作用。大规模临床试验表明,强化降压治疗可显著降低这种风险,因此,美国预防、检测、评估与治疗高血压联合委员会第七次报告指南进一步将糖尿病患者的血压目标降低至<130/80 mmHg。这意味着大多数糖尿病患者需要联合使用两种或更多种抗高血压药物才能达到这一血压目标。虽然糖尿病中最有效的联合治疗策略尚未在大规模随机临床试验中确定,但包含至少一种阻断肾素-血管紧张素系统的药物的联合治疗似乎不仅具有良好的安全性,还可能提供额外的肾脏和心血管保护。应根据患者的风险状况和整体治疗方案添加其他抗高血压药物以实现血压目标。